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Abstract
Objective—To assess social and clinical influences of prostate cancer treatment decisions among
white and black men in the Midlands of South Carolina.
Methods—We linked data collected on treatment decision making in men diagnosed with
prostate cancer from 1996 through 2002 with clinical and sociodemographic factors collected
routinely by the South Carolina Central Cancer Registry (SCCCR). Unconditional logistic
regression was used to assess social and clinical influences on treatment decision.
Results—A total of 435 men were evaluated. Men of both races who chose surgery (versus
radiation) were more likely to be influenced by their physician and by family/ friends. Black men
who chose surgery also were ~5 times more likely to make independent decisions (i.e., rather than
be influenced by their doctor). White men who chose surgery were twice as likely to be influenced
by the desire for cure and less likely to consider the side effects of impotence (odds ratio (OR) =
0.40; 95% confidence interval (CI): 0.18, 0.88) and incontinence (OR = 0.27; 95% CI: 0.12, 0.63);
by contrast, there was a suggestion of an opposite effect in black men, whose decision regarding
surgery tended to be more strongly influenced by these side effects.
Conclusion—Results suggest that both clinical and social predictors play an important role for
men in choosing a prostate cancer treatment, but these influences may differ by race.
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Introduction
Patients diagnosed with prostate cancer are generally presented with three options for
treatment: watchful waiting, radical prostatectomy, or radiotherapy (external beam or
brachytherapy). Other options include cryosurgery, hormonal therapy, or some type of
complementary or alternative medicine. However, no convincing evidence exists to
recommend one prostate cancer treatment over another [1]. Often, patients are encouraged to
take an active role in the decision-making process to choose a course of treatment. However,
the process they use to determine their preference may not be systematic and typically is
influenced by a number of clinical and social factors.
Although the most important issue influencing treatment choice varies widely among
patients, some considerations are more frequently noted as important throughout the
literature. Treatment efficacy and side effects are primary concerns for patients choosing
between treatments. While longevity and cancer control are important to most patients [2-6],
these patients are often willing to trade some longevity for better quality of life, specifically
through an avoidance of impotence and incontinence [7, 8]. Maintaining a balance between
treatment efficacy and the avoidance of side effects is dependent on a patient’s perceptions
of a particular treatment, each having its own advantages and disadvantages.
Surgery (prostatectomy) and radiation (radiotherapy), two of the most common treatment
courses for prostate cancer, have distinct advantages and disadvantages and raise different
concerns with patients. Patients who choose prostatectomy seem to believe strongly that it
represents the best chance of a cure or is the best for longevity [9-12]. These patients
frequently report complete removal of the tumor as a reason that prostatectomy is more
attractive than other treatments [5, 11, 13], but concerns most frequently reported for
surgery are fears of impotence and incontinence and dislike of procedure invasiveness [11,
14]. Men who undergo surgery for prostate cancer treatment have higher rates of both
incontinence and impotence compared to men who choose other options [15]. Patients who
choose radiotherapy report their primary reason for treatment choice is their belief that
radiotherapy is less painful, less invasive, and has fewer, less severe side effects [9-14].
A few studies have examined the role that social factors play in influencing treatment
decisions. Social influences are likely an important component of the decision-making
process for cancer patients and may include personal beliefs and opinions of family, friends,
and physicians. Family and friends often urge men to pursue more active treatments [16],
but the opinions of others who have had cancer treatment and physicians seem to be the
most influential [5, 9, 14, 17-20]. The extent to which social factors influence men to choose
certain treatment types is not well understood.
A few studies have looked for racial differences in factors influencing treatment decision
making. In general, racial differences exist in the type of treatment chosen, with black men
more likely to choose non-surgical options compared to white men [19, 21]. While it is
unclear why these differences exist, some hypothesize that physicians may provide black
men with different information, either because they think these men will not adhere to
medical advice or that they will be less receptive to surgery [19,21]. These treatment choice
disparities also may be a result of physician distrust among black men [22], economic or
social vulnerability, or variation in how black and white men weigh the advantages and
disadvantages of treatment choices [23]. More research is needed in this area, especially
because black men have been found to have significantly higher rates of prostate cancer
incidence and mortality than any other racial or ethnic group [24].
The purpose of this study was to assess the influence of social factors and clinical side
effects on prostate cancer treatment choices among black and white men in the Midlands
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Region of South Carolina. South Carolina is well suited for this study because of the large
proportion of black men and high rates of prostate cancer. In fact, the age-adjusted prostate
cancer mortality rate among black men in South Carolina is among the highest nationwide
[25]. Specifically, we examined the influence of these factors in predicting surgery versus
radiation with data obtained through a short mail questionnaire. This study also assessed
these relationships by race.
Methods
Study cohort
We mailed the questionnaires to men in South Carolina with a previous diagnosis of prostate
cancer from an eight-county area in the Midlands of South Carolina (Calhoun, Fairfield,
Kershaw, Lexington, Newberry, Orangeburg, Richland, and Sumter counties) identified
through the South Carolina Central Cancer Registry (SCCCR). All men diagnosed between
1996 and 2002 were eligible to participate. Both physician and participant consent was
required to participate in the survey. The SCCCR did not release any participant’s
information in which the patient requested not to be contacted or refused participation in
previous research studies. Subsequently, we received a total of 2,079 prostate cancer cases
from the SCCCR.
During the mailing, 103 (5%) questionnaires were undeliverable due to incorrect addresses
or death of the patient. Of those remaining, 1,416 (68%) did not respond after two attempts
to make contact and 9 cases refused to participate. In total, 551 surveys were returned,
yielding a 28% response rate (551/1,976).
Study procedures
Protocols outlined by the Cancer Control Advisory Committee-Surveillance Subcommittee,
the SCCCR, the South Carolina Department of Health and Environmental Control, and the
University of South Carolina Institutional Review Board were implemented to ensure and
maintain confidentiality of prostate cancer patients. Each participant received a cover letter
and survey with a return, self-addressed, stamped envelope. After 1 month, patients who did
not return the survey received a follow-up letter and survey. After 2 months of non-
response, the last attempt was made by mailing the final cover letter and survey.
We linked data from the survey with clinical and sociodemographic factors identified in the
SCCCR. Variables obtained from the registry included age at diagnosis, date of birth, race/
ethnicity, county of residence, marital status, diagnosis year, number of previous cancer
diagnoses, and disease grade and stage categorized according to American Joint Committee
on Cancer [26] staging and histologic grading system for prostate cancer. The grading
system is a marker of pathologic disease severity and ranges with increasing severity from 1
to 4. The stage of a cancer describes to what extent the cancer has spread. The four levels of
stage include local (organ confined), regional (extraprostatic extension), distant (invasion of
surrounding organs), or unknown [26].
Study assessments
The survey was one-page and included twelve questions designed to determine the type of
treatment(s) received and factors that may have affected the decision for choosing a
particular treatment type (Online Resource 1). The survey was created in an optical-scan
program, Teleform®, to assist in survey design and data entry. Exposure variables obtained
from the survey included the person who most influenced the treatment decision, clinical
factors influencing the decision, prostate-specific antigen (PSA) level change, type of
insurance, and access to healthcare.
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The outcome, type of treatment selected, was obtained from the survey. Initial treatment was
categorized as surgery, radiation, chemotherapy, hormone therapy, no treatment (watchful
waiting), and unknown. Change in PSA was determined by self-report of at least one
increase in PSA since receiving cancer treatment. Living with a partner, number of people in
household, insurance status, and transportation to doctor visits were considered as
predictors.
Variable definitions
Due to small sample sizes, we limited our analyses to only those who chose either surgery or
radiation. We excluded men with unknown or “other” race and a distant or unknown tumor
stage. Also, grade was dichotomized into low (grades of 1 or 2: well to moderately
differentiated) versus high (grades of 3 or 4: poorly to undifferentiated). Stage was classified
as either localized or regional (regional included both regional with extensions and regional
to lymph nodes). PSA change was assessed as a dichotomous variable, comparing no PSA
change with ≥1 change in PSA since cancer treatment. Because subjects chose multiple
options for insurance status, this variable was treated individually as four separate
dichotomous variables (Medicaid, Medicare, private insurance, and other). Marital status
was dichotomized as married versus unmarried, and previous cancer diagnoses was
dichotomized as none versus ≥1 previous diagnosis.
Statistical methods
We compared responders to non-responders to determine the representativeness of the study
sample by reviewing the distributions or frequencies of all variables and computing
descriptive statistics. We performed univariable analyses to assess racial, socioeconomic,
and treatment differences in reported factors influencing prostate cancer treatment decisions.
Significant covariates in the univariable models were included in the full model. Because
racial disparities in prostate cancer incidence and treatment choices exist, we considered
race as a covariate regardless of its significance in models.
Unconditional logistic regression analyses were performed with treatment as the dependent
variable dichotomized as surgery versus radiation. We used separate models for social
(doctor, family/friend, self) and clinical (cure, impotence, incontinence, pain) factors, and
also stratified models by race to examine possible effect modification of influential factors
on treatment choice. Results are presented as odds ratios (OR) and corresponding 95%
confidence intervals (CI). All analyses were performed using SAS v.9.1.3 (SAS Institute,
Cary, NC).
Results
Although survey responders (n = 551) were similar to non-responders (n = 1,425) in terms
of tumor grade, responders tended to be younger, more likely to classify themselves as white
and married, and more likely to have a regional tumor stage compared to non-responders
(Table 1). Of responders, six did not provide any treatment information and two responded
that they did not know what type of treatment they received. We excluded nine (2%) men
because they were not of black or white race, 18 (3%) because their tumors were distant or
unstaged, 20 (4%) because their tumors were of an unknown grade, and 47 (9%) because
their treatment was a type other than surgery or radiation or because they chose both surgery
and radiation (n = 14). There were 435 observations remaining for further analyses.
When each factor was evaluated independently, there was a statistically significant increase
in the odds of cases having a regionally staged tumor among those who chose surgery (n =
59) compared to those who chose radiation (n = 8) (Table 2). Those who chose surgery also
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were less likely to have had ≥ change in PSA score, to be younger, unmarried, and to receive
Medicare or Medicaid compared to those who chose radiation (Table 2).
Unconditional logistic regression models (Table 3) examined the relationship between
clinical and social factors and treatment choice after adjustment for confounding variables
identified in univariable models (age at diagnosis, marital status, Medicare and Medicaid
insurance coverage, tumor stage, PSA change, and race). Compared to those who chose
radiation, those who chose surgery were about twice as likely to have been influenced by a
doctor and to consider cure and more than two and a half times more likely to have been
influenced by a family member or friend. Those men choosing surgery also were about 60%
less likely to consider incontinence in their decision making.
When models were stratified by race and adjusted for age at diagnosis and tumor stage,
white and black men who chose surgery were more likely (i.e., >twice and ~5.5 times,
respectively) to have been influenced by a family or friend (Table 4). Black men who chose
surgery were >5 times more likely to have made independent decisions as compared to black
men who chose radiation (Table 4). White men who chose surgery were less likely to
consider impotence and incontinence and more likely to consider cure as important clinical
outcomes compared to white men who chose radiation. No clinical predictors were
identified to be statistically related to treatment choice among black men (Table 4). Despite
the lack of a statistical association, it is notable that black men who chose surgery tended to
consider cure, impotence, and incontinence and not consider pain as important in their
treatment choice when compared to black men who chose radiation.
Discussion
We assessed social and clinical influences on prostate cancer treatment decisions among
black and white men diagnosed with the disease in South Carolina and found that men who
chose surgery were more likely to emphasize the influences of family and/or friends. This is
consistent with the literature, as spouses are more likely to consider total eradication
important [16, 27]. The amount of direct influence that spouses/partners exert on a final
treatment decision is uncertain [27], and results are conflicting [9,28]. For example, some
studies demonstrate that spouses often help to support their husbands and gather
information, but that they leave the final decision making to their husbands [4, 17, 29, 30].
The experiences of people who have had cancer treatment also influences patient treatment
choices [5, 9, 14, 17,18], with friends or colleagues previously diagnosed with prostate
cancer having a stronger influence on treatment decisions than spouses [27]. In one study,
friends were reported as one of the most frequently used sources of information when
making a treatment decision along with the internet and pamphlets provided by the
healthcare provider [18]. Diefenbach et al. [9] found that patients choosing surgery were
influenced by having known other people who had undergone that treatment, and Davidson
et al. [30] found that friends who had been treated for prostate cancer most often
recommended active treatment. Prostate cancer support groups also have been cited as
valuable sources of information and emotional support both before and after treatment [30,
31]. Furthermore, discussing treatment options within one’s social support network has been
shown to promote greater positive emotional affect at 1 and 6 months after treatment,
perhaps fostering greater coping by allowing for emotional expression and cognitive
processing [32].
Although present in men of both races, the influence of family/friends in choosing surgery
was stronger among black men than among white men. Research has shown black men and
women tend to rely heavily on social support from an extended network of family and
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friends, including influences from faith-based networks for making health-related decisions
[25] and have higher levels of medical mistrust [33]. This may explain why the influence
was stronger among black men in our study. Our results also suggest an independent
decision-making influence predicting surgery, especially among black men. It is important
that interventions focus on improving the dissemination of information to men and their
social support system concerning decision making prior to the medical encounter and
encourage participation in shared decision making prior to the final decision.
Overall, men who chose surgery were more likely to consider physicians as an influencing
factor. A previous descriptive study in the same population found that the most important
social influence on prostate cancer treatment decisions was physician advice [34]. Several
other studies have demonstrated that physicians play an influential role in the treatment
decision-making process of their patients [17, 27]. For example, one study showed that
physicians serve as the most common source of information for patients diagnosed with
early-stage (local) prostate cancer [20]. In addition, Hoffman et al. [19] demonstrated that
the treatment recommendation from the physician is the most important determinant of the
treatment that is ultimately chosen. The type of treatment recommended by a physician is
dependent on physician specialty: urologists nearly universally recommend surgery
compared to radiation oncologists, who recommend radiation therapy [27,35]. This is
important because in the United States, a patient suspected of having prostate cancer will be
sent to an urologist for a biopsy who is likely to provide the treatment recommendation [27].
Future studies should strive to collect information on physician specialty.
Participants who chose surgery were more likely to consider cure an important factor than
did participants who chose radiation. They also tended to downplay clinical side effects.
Similarly, other studies have found patients who choose surgery are most concerned with
cancer eradication and likely believe that this treatment type offers the most treatment
efficacy [27, 28]. In fact, the eradication of cancer is a primary concern and important
influence in choosing treatments for most patients [27].
Men who chose surgery for their primary treatment type were less likely to identify
impotence or incontinence as important clinical side effects. The importance of these side
effects is dependent on treatment type, with men concerned about avoiding these side effects
less likely to prefer surgery as compared to other non-surgical options, such as radiation
therapy [27, 28]. Also, cognitive dissonance could very well have played a role: having
made the decision to undergo surgery, men are subsequently more likely to downplay the
importance of these side effects after the fact. Another explanation is that treatment side
effects are relatively less influential on a man’s decision compared to other factors, such as
treatment efficacy. This may be due to deliberately down-weighting these factors or due to a
real lack of knowledge about these clinical side effects either from not receiving accurate
information or from information being presented in a complicated manner [27]. In one
study, only two of five men were unconditionally willing to risk side effects to potentially
gain some longevity [7]. Feldman-Steward et al. [8] found that the chances of dying of
cancer and the effect on the length of life were ranked by less than 20% of patients as one of
the four most important attributes to treatment decision. The four attributes most common
were the following: the effect of the treatment on bladder function, the procedure involved,
effect on sexual functioning, and chance of PSA rising (i.e., as an indicator of recurrence).
Of the possible side effects, incontinence may be the most important influencing factor,
whereas impotence may be less influential in treatment decisions [27]. There is evidence
that the importance placed on side effects varies by race [36-39]. A patient’s perceptions on
how a treatment will affect the issues he finds most important may help explain his
treatment decision.
Wagner et al. Page 6
Cancer Causes Control. Author manuscript; available in PMC 2012 June 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
When stratified, the relationship between choosing radiation and a concern for impotence/
incontinence was only seen among whites. It is noteworthy that black men in the current
study tended to exhibit an opposite trend as compared to whites, with more emphasis on
impotence/ incontinence among black men who chose surgery versus black men who chose
radiation. Although a mechanism behind this discordance is unclear based on these data, it
may be that black men were differentially affected by cognitive dissonance, perhaps blaming
and overstating the influence of these side effects post-surgery. It also may be that black
men are not getting appropriate or understandable information from health professionals
regarding the potential for short- and long-term side effects.
In general, there is substantial variation in the types of treatments and therapies received by
white versus black men, with black men more often receiving less aggressive therapies
compared to white men [23, 27, 40]. A study by Richert-Boe et al. [41] found black men
were offered and received treatment with curative intent less often than their white
counterparts of the same age with the same tumor grade, stage of cancer, and insurance
coverage. Other studies also have demonstrated that black men are less likely to receive
prostatectomies than white men [19, 21]. Importantly, treatment regret also has been
observed in black men and men of low income [40].
Despite the observed variation in this study, there is a paucity of research examining racial
differences in influences involved in this decision-making process [27]. In one qualitative
study, the authors noted that of the 6% of subjects who reported not reading any written
material while making their decision, all were men of color (5 out of 6 African Americans in
the study and 1 out of 1 Asian American). Literacy did not seem to be an issue for these
participants [17]. When asked about this in individual interviews, several of these men said
they felt their physician had provided sufficient information. Several also expressed a sense
of urgency in making a decision quickly to prevent the cancer from spreading. Interestingly,
6 of the 7 non-white participants expressed concern about the spread of the disease as an
influential factor versus only 5 of the 24 white men in the study, a finding that appears to run
counter to the tendency of white men to prefer surgery.
While it is unclear why these observed differences exist, some hypothesize that it may be
due to physician beliefs that black men will be less likely to adhere to medical advice and
will be more likely to experience poor outcomes [19]. Others cite the distrust of physicians
held by black men and women, their fear of surgery [22], as well as physician’s beliefs that
black men and women will be less receptive to recommendations for prostatectomy as being
responsible for these differences [21]. Finally, black men may tend to weigh influencing
factors differently than white men, as they have been found to consider cure less important
and pain more important when making a treatment decision [34]. More research is needed in
this area, especially because black men have been found to have significantly higher rates of
prostate cancer incidence and mortality than any other racial group or ethnic group [24],
especially in South Carolina [25].
We collected data for the current study with a short mail questionnaire that was self-
administered by men previously diagnosed with prostate cancer. Therefore, the data may be
subject to recall bias, although deciding on a course of treatment for cancer is an important
decision that would likely be accurately reported. Additionally, because the survey was
administered after the men made the decision of treatment type, cognitive dissonance may
very well have influenced our results, although the extent to which this occurred is
unknown. This dissonance may have acted in several ways. For example and as noted
earlier, men who chose surgery may subsequently downplay the importance of side effects
in their treatment decision or, alternatively, men who chose surgery and then experienced
side effects as a result of their decision may subsequently overemphasize the importance or
Wagner et al. Page 7
Cancer Causes Control. Author manuscript; available in PMC 2012 June 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
their understanding of side effects in their treatment decision-making process. Studies
collecting similar data prior to decision making and/or the collection of information on the
side effects experienced post-treatment would help circumvent this limitation or allow its
quantification.
Although we had a reasonable response rate (28%), men who responded to the survey were
more likely to be younger, white, married, and diagnosed with more regional tumors.
Despite underrepresentation of black men, we were able to stratify our model by race to
assess important racial differences in the influences of prostate cancer treatment. Future
studies should attempt to obtain a sample with a higher rate of black representation. It is
possible that we received responses from a more health conscious and informed group of
men. The extent to which this may have influenced our results is unknown. Men in good
health are offered surgery more frequently as a treatment for prostate cancer; therefore, our
sample may have included a larger proportion of men who chose surgery. It is also possible
that healthier or more health-conscious men are influenced differently; for example, men in
poorer health may be less concerned about side effects and more concerned about cure.
Additionally, we were unable to evaluate treatments other than surgery and radiation due to
a limited sample size. Future studies should strive to achieve a larger sample size of men
with different treatment types, especially watchful waiting, as this is an important treatment
option for prostate cancer. Despite this limitation, excluding both adjuvant therapies and
hormone therapy excludes the highest-risk tumors, and men with extremely high-risk tumors
may undergo a very different process in selecting treatment.
Our study is one of few to examine the social influences on prostate cancer treatment
choices. Additionally, this study is unique in its examination of racial disparities in these
types of choices. It is important to understand what types of influences—whether they are
personal, social, or clinical—have the greatest impact on decision making in prostate cancer
so that public health officials and physicians can provide better information to relevant
social networks and on relevant clinical topics.
In summary, our study provides an important questionnaire-based assessment of the social
and clinical influences of prostate cancer treatment choices among white and black men in
South Carolina. Our results demonstrate that men of both races who chose surgery were
more likely to be influenced by their physician and family/friends, and black men who chose
surgery were more likely to make independent decisions compared to men who chose
radiation. White men who chose surgery were more likely to be influenced by cure and less
likely to be influenced by the side effects of impotence or incontinence. In contrast, our
results suggest an opposite effect in black men, with those who chose surgery tending to be
more influenced by side effects. Additional studies should seek to further clarify social
influences and racial differences in prostate cancer treatment choices.
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Table 1
Descriptive characteristics of men by response status
Characteristics Responders
(n = 551)
n (%)
Non-respondersa
(n = 1,425)
n (%)
X2 (p value)
Age at diagnosis (mean[SD]) t test 64 (8) 66 (9) 4.1 (<0.0001)
Race 147 (<0.0001)
 White 432 (78) 689 (48)
 Black 110 (20) 699 (49)
 Other 6(1) 20 (1)
 Unknown 3 (0.5) 17 (1)
Marital status 24.9 (<0.0001)
 Unmarried (sep, div, wid) 60 (11) 279 (20)
 Married 471 (85) 1,072 (75)
 Unknown 20 (4) 74 (5)
Tumor grade 4.4 (0.35)
 Well differentiated 42 (8) 125 (9)
 Moderately differentiated 395 (72) 956 (67)
 Poorly differentiated 83 (15) 242 (17)
 Undifferentiated 2 (0.4) 4 (0.3)
 Not determined 29 (5) 98 (7)
Tumor stage 15.3 (0.002)
 Localized 442 (80) 1,149 (81)
 Regional 81 (15) 149 (10)
 Distant metastasized 3 (0.5) 30 (2)
 Unstaged 25 (5) 97 (7)
SD standard deviation
aNon-responders (n = 1,416) and refusals (n = 9)
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Table 2
Univariate statistics modeling the effect of clinical and sociodemographic factors on surgery versus radiation
as a primary prostate cancer treatment type
Variable Surgery Radiation
(n = 253)
n (%)
OR (95% CI)
(n = 182)n (%)
Race
 White 201 (79) 149 (82) 1.00
 Black 52 (21) 33 (18) 1.17 (0.72, 1.90)
Tumor stage
 Localized 194 (77) 174 (96) 1.00a
 Regional 59 (23) 8 (4) 6.62 (3.07, 14.23)
Tumor grade
 Low (grade = 1 or 2) 218 (86) 155 (85) 1.00
 High (grade = 3 or 4) 35 (14) 27 (15) 0.92 (0.54, 1.59)
PSA change
 No change 115 (46) 38 (21) 1.00a
 ≥1 change 134 (54) 140 (79) 0.32 (0.20, 0.49)
Age at diagnosis (years) 61 (7) 68 (8) 0.88 (0.86, 0.91)a
Marital status
 Married 230 (93) 152 (84) 1.00a
 Unmarried 18 (7) 28 (16) 0.43 (0.23, 0.80)
Prior cancer diagnoses
 None 231 (91) 160 (88) 1.00
 ≥1 22 (9) 22 (12) 0.69 (0.37, 1.29)
Insuranceb
 Medicare 160 (63) 153 (84) 0.33 (0.20, 0.52)a
 Medicaid 9 (4) 15 (8) 0.41 (0.18, 0.96)a
 Private 118 (47) 69 (38) 1.43 (0.97, 2.11)
 Other 110 (44) 78 (43) 1.03 (0.70, 1.51)
Social predictors
 Doctor 143 (57) 105 (58) 0.95 (0.65, 1.40)
 Family/friend 70 (28) 32 (18) 1.79 (1.12, 2.87)a
 Yourself 94 (37) 69 (38) 0.97 (0.65, 1.44)
Clinical predictors
 Cure 218 (86) 137 (75) 2.05 (1.25, 3.34)a
 Impotence 41 (16) 60 (33) 0.39 (0.25, 0.62)a
 Incontinence 30 (12) 59 (32) 0.28 (0.17, 0.46)a
 Pain 9(4) 13 (7) 0.48 (0.20, 1.15)
OR odds ratio, CI confidence interval, PSA prostate-specific antigen
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aOverall p value < 0.05
b
Treated as individual dichotomous variable because of multiple responses per individual
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Table 3
Adjusted effects of clinical and social predictors on prostate cancer treatment choice (surgery vs. radiation) (n
= 435)
Variable Odds ratio 95% confidence
interval
Social predictorsa
 Doctor 1.99 1.09, 3.64
 Family/friend 2.64 1.35, 5.14
 Yourself 1.73 0.95, 3.17
Age at diagnosis (years) 0.87 0.84, 0.91
Marital status (vs. married)
 Unmarried 0.65 0.30, 1.42
Insurance
 Medicare 1.22 0.61, 2.43
 Medicaid 0.50 0.17, 1.51
Stage (vs. localized)
 Regional 7.32 3.10, 17.28
PSA change (vs. no change)
 ≥ 1 change 0.33 0.20, 0.54
Race (vs. White)
 Black 0.94 0.51, 1.75
Clinical predictorsa
 Cure 2.37 1.25, 4.50
 Impotence 0.52 0.27, 1.02
 Incontinence 0.42 0.20, 0.84
 Pain 0.84 0.24, 2.93
Age at diagnosis (years) 0.87 0.83, 0.91
Marital status (vs. married)
 Unmarried 0.60 0.27, 1.33
Insurance
 Medicare 1.21 0.59, 2.48
 Medicaid 0.62 0.21, 1.86
Stage (vs. localized)
 Regional 7.18 2.98, 17.33
PSA change (vs. no change)
 ≥ 1 change 0.33 0.19, 0.55
Race (vs. White)
 Black 1.22 0.62, 2.37
Surgery, n = 253. Radiation, n = 182 PSA prostate-specific antigen
aSocial and clinical predictors run in separate logistic regression models
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Table 4
Relationship of clinical and social predictors and prostate cancer treatment choice (surgery vs. radiation),
stratified by race (n = 435)
Variable White (n = 350) Black (n = 85)
Odds ratio 95% CI Odds ratio 95% CI
Social predictorsa
Doctor 1.79 0.95, 3.40 1.95 0.51, 7.42
Family/friend 2.31 1.16, 4.61 5.51 1.21, 25.09
Yourself 1.30 0.69, 2.48 5.35 1.22, 23.60
Age at diagnosis (years) 0.88 0.85, 0.91 0.81 0.73, 0.90
Stage (vs. localized)
Regional 12.88 1.35, 38.11 0.78 0.17, 3.71
Clinical predictors
Cure 2.20 1.07, 4.55 1.87 0.60, 5.80
Impotence 0.40 0.18, 0.88 1.37 0.36, 5.17
Incontinence 0.27 0.12, 0.63 1.55 0.41, 5.95
Pain 1.28 0.28, 5.95 0.33 0.06, 1.76
Age at diagnosis (years) 0.87 0.83, 0.90 0.83 0.75, 0.91
Stage (vs. localized)
Regional 12.34 4.06, 37.56 1.14 0.25, 5.26
Black: Surgery, n = 52. Radiation, n = 33 White: Surgery, n = 201. Radiation, n = 149 CI confidence interval
aSocial and clinical predictors run in separate logistic regression models
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